CN105924333A - Synthesizing method for diphenhydramine pharmaceutical intermediate diphenyl carbinol - Google Patents
Synthesizing method for diphenhydramine pharmaceutical intermediate diphenyl carbinol Download PDFInfo
- Publication number
- CN105924333A CN105924333A CN201610292957.7A CN201610292957A CN105924333A CN 105924333 A CN105924333 A CN 105924333A CN 201610292957 A CN201610292957 A CN 201610292957A CN 105924333 A CN105924333 A CN 105924333A
- Authority
- CN
- China
- Prior art keywords
- solution
- diphenhydramine
- benzohydrol
- synthetic method
- pharmaceutical intermediate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides a synthesizing method for the diphenhydramine pharmaceutical intermediate diphenyl carbinol. Benzophenone and nickel powder are added into a mixed solution of trichloro ethylene and 2-bromine-5-fluoronitrobenzene, and the temperature is slowly increased and maintained for 2-3 h; filtering and washing are carried out 3-5 times, 3 L of a potassium bromide solution is introduced, an oxalic acid solution is added, suction filtration, dehydration with a dehydrating agent and recrystallization are carried out, and diphenyl carbinol crystals are obtained. By means of the synthesizing method, the reaction yield is greatly increased. Meanwhile, the invention provides a novel synthesizing path which lays a good foundation for further increasing the reaction yield.
Description
Technical field
The present invention relates to the preparation method of a kind of medicine intermediate, belong to organic synthesis field, particularly relate to one
Plant the synthetic method of diphenhydramine pharmaceutical intermediate benzohydrol.
Background technology
Diphenhydramine medicine has the effect of antihistaminic H1 receptor, has stronger inhibitory action to nervus centralis,
Also has atropine-like effect.It is suitable for Mucocutaneous anaphylactic disease, such as urticaria, pollinosis, anaphylaxis
Rhinitis etc..For the derivant of ethanolamine, antihistamine effect is not as good as promethazine, and acting duration is the shortest,
Sedation two medicine is consistent.Also there are local anaesthesia, the anti-M-choline-like effect of Tuhe, town.Histamine effect: can be with tissue
In H1 receptor on the histamine competitive effect cell that discharges, thus prevent allergy outbreak;Tranquilizing soporific is made
With: the mechanism of suppression neural activity is still not clear;Antitussive effect: can be done directly on the cough of oblongata
Maincenter, suppresses coughre flex.The anaphylaxis caused by blood transfusion or blood plasma can be alleviated;Usually should before blood transfusion
With antihistamine drug's such as diphenhydramine etc., generally give diphenhydramine 40 milligrams of intramuscular injection, note donating blood simultaneously
The screening of member, does not use the blood donor of allergies as far as possible.Avoid the blood of the same blood donor of infusion repeatedly,
To avoid antigen-antibody reaction, during as there are anti-IgA antibody in donee's body, can be with infusion through washing
Erythrocyte after washing, this washing methods can remove the IgA in donor blood, to prevent anaphylactoid
Raw.There is the effect of telling of stronger town it can also be used to prevent and treat radiation sickness, Post operation vomiting, drug-induced nauseating
Vomiting;For parkinson disease and extrapyramidal symptoms;Calmness, for hypnosis and preoperative administration;Dentistry local anaesthesia,
When patient is to conventional local anaesthetics hyperirritability, 1% diphenhydramine liquid can be as dental local anaesthetics;Hexichol
Base methanol is as diphenhydramine pharmaceutical intermediate, and its synthetic method is good and bad for improving pharmaceutical synthesis product quality,
Reduce by-products content and there is Important Economic meaning.
Zhang Pengfei (Zhang Pengfei, Gu Haining, Ge Haiquan, Li little Ling. the conjunction of α, α-diphenyl-4-piperidine carbinols
Become and cleavage of mass spectrum research [J]. Journal of Hangzhou Teachers College (natural science edition), 2006,04:315-318.)
Benzophenone is added in dimethylbenzene with 4-cyanopyridine, adds metallic sodium under nitrogen protection, then heat back
Stream reaction, cooling decompression filters, washs, dries, and may finally obtain 4-pyridine radicals benzohydrol.Should
Hydrogenation reaction uses free radical idol association response, and catalytic hydrogenation etc. is synthesized 4-pyridine radicals benzohydrol,
Reaction yield only has 60%, and this synthetic method is unfavorable for the raising of reaction yield, therefore, anti-in order to improve
Answer yield, it is necessary to propose a kind of new synthetic method.
Summary of the invention
The technical problem existed based on background technology, the present invention proposes a kind of diphenhydramine pharmaceutical intermediate two
The synthetic method of phenyl methanol.
The synthetic method of a kind of diphenhydramine pharmaceutical intermediate benzohydrol, comprises the steps:
A, in the reaction vessel being provided with agitator, reflux condenser, thermometer, add benzophenone (change
Formula 2) 0.32mol, trichloro ethylene solution 800-900ml, 2-bromo-5-fluoronitrobenzene solution 1.38mol, nikel powder
0.81mol, controls mixing speed 110-150rpm, and slowly rising solution temperature is to 80 DEG C, and temperature-rise period controls
At 90-110min, maintain 2-3h;
B, filtration, filter cake propionitrile solution washs 3-5 time, and merging filtrate and cleaning mixture import 3L potassium bromide
In solution, adding oxalic acid solution 500-600ml, separate out solid, sucking filtration, dehydrant is dehydrated, at nitromethane
Recrystallization in solution, obtains crystal benzohydrol (chemical formula 1).
Preferably, described trichloro ethylene liquid quality fraction is 30-42%.
Preferably, described 2-bromo-5-fluoronitrobenzene liquid quality fraction is 20-35%.
Preferably, described propionitrile liquid quality fraction is 33-48%.
Preferably, described potassium bromide solution mass fraction is 10-18%.
Preferably, described oxalic acid solution mass fraction is 23-36%.
Preferably, described dehydrant is any one in sodium sulfate, calcium oxide.
Preferably, described nitromethane solution mass fraction is 55-63%.
Whole course of reaction can represent with following reaction equation:
Compared to synthetic method disclosed in background technology, the diphenhydramine pharmaceutical intermediate hexichol that the present invention provides
The synthetic method of base methanol, reaction yield is greatly improved, and the invention provides a kind of new synthetic route simultaneously,
Lay a good foundation for promoting reaction yield further.
Accompanying drawing explanation
Fig. 1 is the mass fraction of the trichloro ethylene solution normal distribution on the impact of reaction yield.Wherein,
Abscissa is the mass fraction of trichloro ethylene solution;Vertical coordinate is reaction yield;
Fig. 2 is the mass fraction of the 2-bromo-5-fluoronitrobenzene solution normal distribution on the impact of reaction yield.
Wherein, abscissa is the mass fraction of 2-bromo-5-fluoronitrobenzene solution;Vertical coordinate is reaction yield;
Fig. 3 is the mass fraction of the propionitrile solution normal distribution on the impact of reaction yield.Wherein, horizontal seat
It is designated as the mass fraction of propionitrile solution;Vertical coordinate is reaction yield;
Fig. 4 is the mass fraction of the potassium bromide solution normal distribution on the impact of reaction yield.Wherein, horizontal
Coordinate is the mass fraction of potassium bromide solution;Vertical coordinate is reaction yield.
Detailed description of the invention
Embodiment 1:
The synthetic method of a kind of diphenhydramine pharmaceutical intermediate benzohydrol, follows the steps below:
In the reaction vessel being provided with agitator, reflux condenser, thermometer, add benzophenone 0.32mol,
Mass fraction is the trichloro ethylene solution 900ml of 38%, mass fraction be 30% 2-bromo-5-fluoronitrobenzene molten
Liquid 1.38mol, nikel powder 0.81mol, control mixing speed 150rpm, and slowly rising solution temperature is to 80 DEG C, rises
Temperature process control, at 110min, maintains 3h, filters, and filter cake mass fraction is that 40% propionitrile solution washs 5 times,
Merging filtrate and cleaning mixture, import in the potassium bromide solution that 3L mass fraction is 15%, adds mass fraction and is
The oxalic acid solution 600ml of 30%, separates out solid, sucking filtration, and sodium sulfate agent is dehydrated, is 59% at mass fraction
Nitromethane solution in recrystallization, obtain crystal benzohydrol 51.23g, yield 87%.
Embodiment 2:
The synthetic method of a kind of diphenhydramine pharmaceutical intermediate benzohydrol, follows the steps below:
In the reaction vessel being provided with agitator, reflux condenser, thermometer, add benzophenone 0.32mol,
Mass fraction is the trichloro ethylene solution 850ml of 38%, mass fraction be 27% 2-bromo-5-fluoronitrobenzene molten
Liquid 1.38mol, nikel powder 0.81mol, control mixing speed 130rpm, and slowly rising solution temperature is to 80 DEG C, rises
Temperature process control, at 100min, maintains 2h, filters, and filter cake mass fraction is the propionitrile solution washing 4 of 39%
Secondary, merging filtrate and cleaning mixture, import in the potassium bromide solution that 3L mass fraction is 15%, add quality and divide
Number is the oxalic acid solution 550ml of 27%, separates out solid, sucking filtration, and calcium oxide dehydrant is dehydrated, at mass fraction
It is recrystallization in the nitromethane solution of 58%, obtains crystal benzohydrol 48.87g, yield 83%.
Embodiment 3:
The synthetic method of a kind of diphenhydramine pharmaceutical intermediate benzohydrol, follows the steps below:
In the reaction vessel being provided with agitator, reflux condenser, thermometer, add benzophenone 0.32mol,
Mass fraction is the trichloro ethylene solution 800ml of 30%, mass fraction be 20% 2-bromo-5-fluoronitrobenzene molten
Liquid 1.38mol, nikel powder 0.81mol, control mixing speed 110rpm, and slowly rising solution temperature is to 80 DEG C, rises
Temperature process control, at 90min, maintains 2h, filters, and filter cake mass fraction is the propionitrile solution washing 3 of 33%
Secondary, merging filtrate and cleaning mixture, import in the potassium bromide solution that 3L mass fraction is 10%, add quality and divide
Number is the oxalic acid solution 500ml of 23%, separates out solid, sucking filtration, and sodium sulfate agent is dehydrated, at mass fraction
It is recrystallization in the nitromethane solution of 55%, obtains crystal benzohydrol 47.69g, yield 81%.
The yield of embodiment 1-3 is above 80%, therefore synthetic method ratio provided by the present invention is in background technology
Synthetic method, reaction yield is greatly improved.
Below embodiment 4-9 is contrasted with embodiment 1, the percent mass comparison of each solution in research reaction
The impact of yield.
Embodiment 4:
Being adjusted by the mass fraction of the trichloro ethylene solution in embodiment 1, remaining preparation condition is joined with raw material
Ratio is same as in Example 1, obtains reaction yield as follows:
Table one: the mass fraction of the trichloro ethylene solution impact on reaction yield
From embodiment 4, the mass fraction of trichloro ethylene solution is too high or too low all can affect reaction yield,
It becomes normal distribution (Fig. 1) with reaction yield, and it is 30-42% that peak value occurs in mass fraction.
Embodiment 5:
The mass fraction of bromo-for the 2-in embodiment 1 5-fluoronitrobenzene solution is adjusted, remaining preparation condition
Same as in Example 1 with proportioning raw materials, obtain reaction yield as follows:
The impact on reaction yield of the mass fraction of table two: 2-bromo-5-fluoronitrobenzene solution
From embodiment 5, the mass fraction of 2-bromo-5-fluoronitrobenzene solution is too high or too low all can be affected instead
Answering yield, it becomes normal distribution (Fig. 2) with reaction yield, and it is 20-35% that peak value occurs in mass fraction.
Embodiment 6:
The mass fraction of the propionitrile solution in embodiment 1 is adjusted, remaining preparation condition and proportioning raw materials with
Embodiment 1 is identical, obtains reaction yield as follows:
Table three: the mass fraction of the propionitrile solution impact on reaction yield
Propionitrile liquid quality fraction % | 20 | 25 | 28 | 33 | 40 | 48 | 51 | 56 | 60 |
Reaction yield % | 67 | 69 | 74 | 81 | 86 | 84 | 78 | 72 | 68 |
From embodiment 6, the mass fraction of propionitrile solution is too high or too low all can affect reaction yield, its with
Reaction yield becomes normal distribution (Fig. 3), and it is 33-48% that peak value occurs in mass fraction.
Embodiment 7:
The mass fraction of the potassium bromide solution in embodiment 1 is adjusted, remaining preparation condition and proportioning raw materials
Same as in Example 1, obtain reaction yield as follows:
Table four: the mass fraction of the potassium bromide solution impact on reaction yield
Potassium bromide solution mass fraction % | 3 | 5 | 8 | 10 | 14 | 18 | 20 | 24 | 28 |
Reaction yield % | 70 | 72 | 74 | 82 | 87 | 85 | 79 | 76 | 73 |
From embodiment 7, the mass fraction of potassium bromide solution is too high or too low all can affect reaction yield, its
Become normal distribution (Fig. 4) with reaction yield, it is 10-18% that peak value occurs in mass fraction.
Embodiment 8:
The mass fraction of the oxalic acid solution in embodiment 1 is adjusted, remaining preparation condition and proportioning raw materials with
Embodiment 1 is identical, obtains reaction yield as follows:
Table five: the mass fraction of the oxalic acid solution impact on reaction yield
Oxalic acid solution mass fraction % | 13 | 15 | 18 | 23 | 29 | 36 | 41 | 45 | 50 |
Reaction yield % | 70 | 75 | 77 | 84 | 86 | 86 | 86 | 87 | 87 |
From embodiment 8, reaction yield can raise along with the raising of the mass fraction of oxalic acid solution, but matter
After amount mark is higher than 23%, promoting speed and substantially slow down, therefore consider cost, preferred mass fraction is
23-36%.
Embodiment 9:
Being adjusted by the mass fraction of the nitromethane solution in embodiment 1, remaining preparation condition is joined with raw material
Ratio is same as in Example 1, obtains reaction yield as follows:
Table six: the mass fraction of nitromethane solution is on reaction yield and the impact of recrystallization time
From embodiment 9, reaction yield is had little to no effect by the mass fraction of nitromethane solution, but
It is bigger to the time effects of recrystallization, it is considered to cost, and preferred mass fraction is 55-63%.
Described in above example, the only present invention preferably detailed description of the invention, but protection scope of the present invention
Be not limited thereto, any those familiar with the art in the technical scope that the invention discloses,
According to technical scheme and inventive concept equivalent or change in addition thereof, all should contain in the present invention
Protection domain within.
Claims (8)
1. the synthetic method of a diphenhydramine pharmaceutical intermediate benzohydrol, it is characterised in that include as
Lower step:
A, in the reaction vessel being provided with agitator, reflux condenser, thermometer, add benzophenone 0.32mol,
Trichloro ethylene solution 800-900ml, 2-bromo-5-fluoronitrobenzene solution 1.38mol, nikel powder 0.81mol, control to stir
Mixing speed is 110-150rpm, and slowly rising solution temperature is to 80 DEG C, and temperature-rise period controls at 90-110min,
Maintain 2-3h;
B, filtration, filter cake propionitrile solution washs 3-5 time, and merging filtrate and cleaning mixture import 3L potassium bromide
In solution, adding oxalic acid solution 500-600ml, separate out solid, sucking filtration, dehydrant is dehydrated, at nitromethane
Recrystallization in solution, obtains crystal benzohydrol.
2. the synthetic method of diphenhydramine pharmaceutical intermediate benzohydrol as claimed in claim 1, its feature
Being, described trichloro ethylene liquid quality fraction is 30-42%.
3. the synthetic method of diphenhydramine pharmaceutical intermediate benzohydrol as claimed in claim 1, its feature
Being, described 2-bromo-5-fluoronitrobenzene liquid quality fraction is 20-35%.
4. the synthetic method of diphenhydramine pharmaceutical intermediate benzohydrol as claimed in claim 1, its feature
Being, described propionitrile liquid quality fraction is 33-48%.
5. the synthetic method of diphenhydramine pharmaceutical intermediate benzohydrol as claimed in claim 1, its feature
Being, described potassium bromide solution mass fraction is 10-18%.
6. the synthetic method of diphenhydramine pharmaceutical intermediate benzohydrol as claimed in claim 1, its feature
Being, described oxalic acid solution mass fraction is 23-36%.
7. the synthetic method of diphenhydramine pharmaceutical intermediate benzohydrol as claimed in claim 1, its feature
Being, described dehydrant is any one in sodium sulfate, calcium oxide.
8. the synthetic method of diphenhydramine pharmaceutical intermediate benzohydrol as claimed in claim 1, its feature
Being, described nitromethane solution mass fraction is 55-63%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610292957.7A CN105924333A (en) | 2016-05-05 | 2016-05-05 | Synthesizing method for diphenhydramine pharmaceutical intermediate diphenyl carbinol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610292957.7A CN105924333A (en) | 2016-05-05 | 2016-05-05 | Synthesizing method for diphenhydramine pharmaceutical intermediate diphenyl carbinol |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105924333A true CN105924333A (en) | 2016-09-07 |
Family
ID=56834520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610292957.7A Pending CN105924333A (en) | 2016-05-05 | 2016-05-05 | Synthesizing method for diphenhydramine pharmaceutical intermediate diphenyl carbinol |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105924333A (en) |
-
2016
- 2016-05-05 CN CN201610292957.7A patent/CN105924333A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11214548B2 (en) | Cannabinoid receptor modulators | |
CN109689673B (en) | C17, C20 and C21 substituted neuroactive steroids and methods of use thereof | |
JP7125385B2 (en) | TLR7/8 antagonists and their uses | |
JP2022066289A (en) | Cannabinoid receptor modulators | |
JP2023535701A (en) | Functionalized peptides as antiviral agents | |
JP2020015743A (en) | Pyrazolyl-urea as kinase inhibitor | |
JP6801159B2 (en) | Imidazoisoindole derivative, its manufacturing method and its pharmaceutical use | |
WO2017106607A1 (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
EP3640248B1 (en) | Aminopyrimidine derivatives, preparation method therefor and use thereof | |
WO2010092962A1 (en) | Hetero ring derivative | |
CA3144701A1 (en) | Compositions and methods for treating cns disorders | |
CA2540186A1 (en) | Phenyl-piperazine derivatives as modulators of muscarinic receptors | |
CA2741661A1 (en) | Novel amide derivative and use thereof as medicine | |
CN100516040C (en) | Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl | |
AU2013350819A1 (en) | Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia | |
CN111825611A (en) | 4(1H) -quinovone derivatives and uses thereof | |
AU2022244467A1 (en) | 1,3-substituted cyclobutyl derivatives and uses thereof | |
JP2021035910A (en) | Substituted purine compound | |
TW202409017A (en) | Heterocyclic compounds, preparation method and medical use thereof | |
CA3157657A1 (en) | 1,2,4-oxadiazole derivatives as liver x receptor agonists | |
CA2967694A1 (en) | Indole and azaindoles derivatives and their use in neurodegenerative diseases | |
EP4083032A1 (en) | Pd-l1 antagonist compound | |
CN105924333A (en) | Synthesizing method for diphenhydramine pharmaceutical intermediate diphenyl carbinol | |
CA3214360A1 (en) | Pyrimidine derivatives useful as lrrk2 kinase inhibitors | |
JPWO2005079845A1 (en) | Migraine prophylaxis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160907 |
|
RJ01 | Rejection of invention patent application after publication |